Earnings Preview: Esperion Therapeutics
Portfolio Pulse from Benzinga Insights
Esperion Therapeutics (NASDAQ:ESPR) is scheduled to release its quarterly earnings report on February 27, 2024, with analysts expecting an EPS of $-0.48. The company's past earnings performance shows a mix of beats and misses, with the share price reacting variably. Shares are currently trading at $2.61, down 57.04% over the last year. Investors will be keenly watching for not just the earnings outcome but also the company's guidance for future growth.
February 26, 2024 | 8:02 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Esperion Therapeutics is expected to report an EPS of $-0.48 for the upcoming quarter. Historical performance shows variable stock price reactions to earnings outcomes. Currently trading at $2.61, down significantly over the past year.
Given Esperion Therapeutics' mixed past earnings performance and the significant year-to-date decline in share price, the upcoming earnings report and particularly the future guidance provided by the company will be crucial for short-term stock movement. However, the historical data shows that the stock's reaction to earnings reports can be unpredictable, hence the neutral score.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100